Spraying spray bottle
Nasal Vaccines Are Commercially High Risk, Perhaps High Reward
Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?
Nasal Vaccines Are Commercially High Risk, Perhaps High Reward
Nasal Vaccines Are Commercially High Risk, Perhaps High Reward

Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?

Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?

pharma & biotech
Zebrafish with fluorescent nervous system in green.
Oust the Mouse: A Plan to Reduce Mammal Use in Drug Development
Natalia Mesa | Mar 15, 2022
The Scientist spoke to Mount Desert Island Biological Laboratory’s Jim Strickland about the institute’s new MDI Bioscience initiative to perform more drug testing and development in nonmammalian models.
Man in personal protective equipment (glasses, gloves, cap, and coat) watching plants go through a piece of machinery.
Canada Approves World’s First Plant-Based COVID-19 Vaccine
Natalia Mesa | Feb 25, 2022
Canada has ordered 76 million doses of Covifenz, the main ingredient of which was manufactured in the leaves of a tobacco relative.
Thwarting a Pandemic: COVID-19 Vaccine Strategies
The Scientist Creative Services Team
Download this poster to learn about promising vaccine candidates for COVID-19!
Photo of lab-grown chicken from Eat Just, Inc.
Cultured Meat Advances Toward the Market
Abby Olena | Feb 14, 2022
The biotech industry is chipping away at the obstacles standing between the lab and the dinner plate.
DNA
In Editing RNA, Researchers See Endless Possibilities
Christie Wilcox | Dec 1, 2021
RNA editing has been in DNA editing’s shadow for nearly a decade, but recent investments in the technology could bring it into the limelight.
Starting a New Lab
The Scientist Creative Services Team
Advice for new principal investigators starting their first research laboratories!
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist Staff | Dec 1, 2021
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Infographic showing endogenous adenosine enzymes acting on RNA (ADARs) edit genetic material in the cell by attaching to naturally occurring double-stranded RNAs, including mRNAs, and switching out A bases with I bases (left). Therapeutic RNA editing platforms based on this mechanism fall into one of two categories: either they use engineered enzymes, which generally consist of the editing part of the ADAR enzyme attached to another protein such as Cas13 that boosts specificity, alongside a guide RNA that targets the enzyme to the desired location (middle); or they consist of a guide RNA alone, which recruits an endogenous ADAR to edit the target sequence (right).
Infographic: RNA Editing Approaches
Christie Wilcox | Dec 1, 2021
RNA editing platforms leverage the natural activity of ADAR enzymes to make key changes to messenger RNAs before they are translated into proteins.
blue and white building sign
Biden Picks Robert Califf to Head the FDA for a Second Time
Chloe Tenn | Nov 12, 2021
The cardiologist was briefly the FDA Commissioner in the Obama Administration, and now has a second chance to act on plans he tried to implement during his first tenure.
Brain cells with electrical firing. 3D rendering.
Microglia as Therapeutic Targets in Neurodegenerative Diseases
Sruthi S. Balakrishnan | Oct 1, 2021
Pharmaceutical companies ramp up efforts to get the brain’s immune cells to help treat Alzheimer’s disease and other conditions, but not everyone agrees the approach will be effective.
Women looks at computer screen in a lab coat and mask
Quest for Research Freedom Fuels African Biotech Boom
Linda Nordling | Jul 1, 2021
Tired of dancing to the tunes of international funders, and doubtful that long-promised national grants will come, a handful of African biomedical scientists have turned to private investors to bankroll their dreams of autonomy in the lab.
A person wearing a purple glove holds out a blue pill
Fecal Microbiota Transplantation Is Poised for a Makeover
Shawna Williams | Jun 1, 2021
With multiple microbiota therapeutics in the pipeline for recurrent Clostridium difficile infection, clinicians foresee a shift in treatment options for the condition.
clear blood draw tubes with peach-colored caps and white labels with a red banner that has a DNA double helix icon and the word text. inside the tubes is a conceptual drawing of a DNA double helix in white
FDA-Led Consortium Details Improvements Needed in Liquid Biopsies
Marcus A. Banks | May 19, 2021
In the largest effort to date to standardize performance metrics of the cancer diagnostic across products, researchers say the products can likely detect advanced tumors reliably, but early-stage malignancies would remain a challenge.
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Rachael Moeller Gorman | Apr 1, 2021
Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.
Moncef Slaoui Fired by GSK Amid Sexual Harassment Claims
Lisa Winter | Mar 24, 2021
The former GlaxoSmithKline executive had led the US government’s Operation Warp Speed COVID-19 vaccine program during the Trump administration.
SEC Charges uBiome Founders with Defrauding Investors
Catherine Offord | Mar 23, 2021
The microbiome-testing company made misleading claims about its prospects and about its business strategy, which allegedly relied on fooling doctors into ordering unnecessary tests, according to the US government.
José Baselga, cancer, research, oncology, AstraZeneca, breast cancer, drugs, therapeutics, obituary, dies
José Baselga, Renowned Oncologist, Dies at 61
Asher Jones | Mar 22, 2021
The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.
Gene Therapy for Sickle Cell Not Linked to Cancer, Bluebird Finds
Lisa Winter | Mar 11, 2021
Clinical trials were halted after the treatment’s vector that ferries in the healthy genetic sequence was identified in the genome of a patient’s cancer cells.
aripiprazole ability autism spectrum behavior review
Spectrum Reporting Prompts New Review of Common Drug
Jaclyn Jeffrey-Wilensky | Feb 11, 2021
The review of more than two dozen studies finds aripiprazole has side effects and does not change core autism features, but parents report improvements in self-injury, tantrums, and other challenging behaviors.